Literature DB >> 23551197

An exploratory microdialysis study investigating the effect of repeated application of a diclofenac epolamine medicated plaster on prostaglandin concentrations in skeletal muscle after standardized physical exercise.

Angela Burian1, Valeria Frangione, Stefano Rovati, Giuseppe Mautone, Chiara Leuratti, Angelo Vaccani, Richard Crevenna, Mohammad Keilani, Bernhard Burian, Martin Brunner, Markus Zeitlinger.   

Abstract

AIM: Muscle injuries and extensive exercise are associated with cyclo-oxygenase dependent formation of inflammatory prostaglandins. Since the effect of topical administration of non-steroidal anti-inflammatory drugs (NSAIDs) on local cyclo-oxygenase is unknown, the present exploratory, open label, non-randomized study set out to measure exercise induced release of prostaglandins before and after epicutaneous administration of diclofenac.
METHODS: Microdialysis was used to determine the local interstitial concentration of PGE2 and 8-iso-PGF2α as well as diclofenac concentrations in the vastus lateralis under rest, dynamic exercise and during recovery in 12 healthy subjects at baseline and after a treatment phase applying a total of seven plasters medicated with 180 mg of diclofenac epolamine over 4 days.
RESULTS: At baseline PGE2 concentrations were 1169 ± 780 pg ml(-1) at rest and 1287 ± 459 pg ml(-1) during dynamic exercise and increased to 2005 ± 1126 pg ml(-1) during recovery. After treatment average PGE2 concentrations were 997 ± 588 pg ml(-1) at rest and 1339 ± 892 pg ml(-1) during exercise. In contrast with the baseline phase no increase in PGE2 concentrations was recorded during the recovery period after treatment (PGE2 1134 ± 874 pg ml(-1)). 8-iso-PGF2α was neither affected by exercise nor by treatment with diclofenac. Local and systemic concentrations of diclofenac were highly variable but comparable with previous clinical pharmacokinetic studies.
CONCLUSIONS: We can hypothesize an effect of topical diclofenac epolamine plaster on limiting the increase of local concentrations of the pro-inflammatory prostaglandin PGE2 induced in the muscle of healthy human subjects following standardized physical exercise. No effect of diclofenac treatment on 8-iso-PGF2α concentrations was observed, mainly since isoprostane is produced by a free radical-catalyzed lipid peroxidation mechanism independent of cyclo-oxygenases.
© 2013 The Authors. British Journal of Clinical Pharmacology © 2013 The British Pharmacological Society.

Entities:  

Keywords:  diclofenac; microdialsis; pharmacokinetics; transdermal

Mesh:

Substances:

Year:  2013        PMID: 23551197      PMCID: PMC3845311          DOI: 10.1111/bcp.12125

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method.

Authors:  M R Bouw; M Hammarlund-Udenaes
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

Review 2.  Prostaglandin E2 and pain--an update.

Authors:  Atsufumi Kawabata
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

3.  F(2)-isoprostane and prostaglandin F(2 alpha)metabolite excretion rate and day to day variation in healthy humans.

Authors:  J Helmersson; S Basu
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2001-08       Impact factor: 4.006

4.  Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation.

Authors:  Martin Brunner; Pejman Dehghanyar; Bernd Seigfried; Wolfgang Martin; Georg Menke; Markus Müller
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

Review 5.  Topical diclofenac and its role in pain and inflammation: an evidence-based review.

Authors:  J Zacher; R Altman; N Bellamy; P Brühlmann; J Da Silva; E Huskisson; R S Taylor
Journal:  Curr Med Res Opin       Date:  2008-02-14       Impact factor: 2.580

6.  Application of microdialysis to clinical pharmacokinetics in humans.

Authors:  M Müller; R Schmid; A Georgopoulos; A Buxbaum; C Wasicek; H G Eichler
Journal:  Clin Pharmacol Ther       Date:  1995-04       Impact factor: 6.875

7.  Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain.

Authors:  Maria Burian; Irmgard Tegeder; Maic Seegel; Gerd Geisslinger
Journal:  Clin Pharmacol Ther       Date:  2003-08       Impact factor: 6.875

8.  Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion.

Authors:  G Gallacchi; R Marcolongo
Journal:  Drugs Exp Clin Res       Date:  1993

9.  Diclofenac/N-(2-hydroxyethyl)pyrrolidine: a new salt for an old drug.

Authors:  A Fini; G Fazio; I Rapaport
Journal:  Drugs Exp Clin Res       Date:  1993

10.  Diclofenac epolamine topical patch relieves pain associated with ankle sprain.

Authors:  David R Lionberger; Eric Joussellin; Arturo Lanzarotti; Jillmarie Yanchick; Merrell Magelli
Journal:  J Pain Res       Date:  2011-03-07       Impact factor: 3.133

View more
  1 in total

1.  Diclofenac in vitro microdialysis study comparing different experimental set-ups to improve quantitative recovery.

Authors:  Anselm Jorda; Marianna Armogida; Edith Lackner; Sivasankari Saikumar; Filip Sucharski; Maria Weber; Markus Zeitlinger
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-02-02       Impact factor: 3.688

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.